biomonitor 代理

详细介绍

产品咨询

世界*实验材料供应商 Biomonitor正式上海金畔为其中国代理， Biomonitor在一直是行业的*,一直为广大科研客户提供zui为优质的产品和服务,上海金畔一直秉承为中国科研客户带来的产品，的服务， Biomonitor就是为了给广大科研客户带来更加完善的产品和服务,您的满意将是我们zui大的收获

 Biomonitor中国代理, Biomonitor上海代理， Biomonitor北京代理，Biomonitor广东代理， Biomonitor江苏代理Biomonitor 湖北代理,Biomonitor天津,Biomonitor黑龙江代理,Biomonitor内蒙古代理,Biomonitor吉林代理,Biomonitor福建代理, Biomonitor江苏代理, Biomonitor浙江代理, Biomonitor四川代理,

丹麦Biomonitor www.biomonitor.dk
Biomonitor A/S 是一家位于丹麦的未上市公司，创立于2003年，由丹麦 Sunstone Capital 提供资助。该公司是开发创新型可靠检测技术并将这些测试融入大型*患者监测计划的公司之一。除了面向多发性硬化患者的监测计划之外，该公司还为接受抗 TNF 药物治疗的患者提供实验室测试服务（药物的循环水平和抗药抗体的监测），并作为一家专业化合同研究组织 (CRO) 为药物和生物技术行业的多种生物药物开发计划提供支持。Biomonitor Limited 是 Biomonitor A/S 的全资子公司，位于爱尔兰戈尔韦，是一家获得 ISO 认证的生产机构。

Biomonitor A/S is a privay held Danish company founded in 2003 and funded by Sunstone Capital, Denmark. The company is among the leaders in developing innovative, reliable assay technologies and incorporating these tests into large and comprehensive patient-monitoring programs. In addition to monitoring programs for MS patients, the company offers laboratory-testing services for patients on anti-TNF drug therapy (both circulating levels of drug and detection of ADAs, and, as a specialized CRO, supports the pharma and biotech industry in their drug-development programs for many classes of biological drugs. Biomonitor Limited is Biomonitor A/S’s wholly owned subsidiary located in Galway, Ireland and is an ISO-certified manufacturing facility.

Biomonitor was founded in 2003 by Professor Klaus Bendtzen and Arsalan Kharazmi as a spinout from the University of Copenhagen and has since its inception grown rapidly.

The foundation of the company is based on Professor Klaus Bendtzen’s many years of experience from his research work at the Copenhagen University Hospital on inflammation and immunology. Prof. Klaus Bendtzen discovered through his work how some patients form antibodies against those proteins and peptides that are used in biopharmaceutical products for the treatment of a range of chronic diseases. Antibodies can neutralize the biopharmaceuticals that patients receive and patients with antibodies thereby do not or only marginally benefit from such treatments so it became crucial to develop methods to monitor biopharmaceuticals.

Biopharmaceutical treatments are very costly and potentially dangerous. Consequently, it makes good sense to monitor patients so that the drugs can be tailored to the individual patient and so that physicians early on can deal with patients who develop antibodies. By doing this, patients, society and insurance companies can save tremendous amount of resources and the patient can be relieved from a treatment that does not work as designed. Most biopharmaceutical treatments are relatively new, and Biomonitor is one of the leading companies in the field, which monitors these therapies.

In November 2008 Biomonitor acquired Neutekbio Ltd. With its proprietary platform of products based on reporter gene technology and developed cell-based assays and kits called iLite™, Neutekbio Ltd. complements Biomonitor’s offerings in assays for patient monitoring and biopharmaceutical drug development programs. The discovery research is performed through a collaborative research and development agreement with the Laboratory of Viral Oncology (The Centre National Recherché Scientifique) in the Institute Andre Lwoff, Villejuif, France. These research programs have been carried out under the direction of Dr. Michael Tovey, an international leader in cytokine research and interferon therapy.

上海金畔生物科技有限公司